Saturn V Capital Management LP — 13F Holdings & Portfolio
CIK 1964437 · latest 13F-HR filed 2026-05-15
Saturn V Capital Management LP manages $552.2M in 13F-reported U.S. long-equity assets across 21 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are ALMS (12.77%), AMLX (10.95%), ABVX (10.94%). Quarter over quarter (versus its 2025-12-31 filing) the fund opened 4 new positions, exited 3, added to 9, and trimmed 7.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
$552.2M
Long-equity book
21
Distinct positions
2026-03-31
Filed 2026-05-15
+4 / −3 / ↑9 / ↓7
vs 2025-12-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- ALUMIS INC$39.9M +130.5%
- IMMIX BIOPHARMA INC$18.0M +114.5%
- VAXCYTE INC$11.1M +30.0%
- AMYLYX PHARMACEUTICALS INC$6.1M +11.3%
- OVID THERAPEUTICS INC$5.2M +127.0%
Top Trims
- ABIVAX SA-$27.1M -31.0%
- COGENT BIOSCIENCES INC-$19.1M -44.2%
- DYNE THERAPEUTICS INC-$17.5M -49.9%
- JAZZ PHARMACEUTICALS PLC-$11.4M -26.9%
- INVIVYD INC-$4.9M -25.5%
New Positions
- CANDEL THERAPEUTICS INC$14.2M
- ZURA BIO LTD$4.4M
- ALTO NEUROSCIENCE INC$2.0M
- SATELLOS BIOSCIENCE INC$2.0M
Exited Positions
- OCULAR THERAPEUTIX INC$18.3M
- CENTESSA PHARMACEUTICALS PLC$7.1M
- INVENTIVA SA$1.3M
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | ALUMIS INC | ALMS | 022307102 | $70.5M | 12.77% | 3,202,075 | SH |
| 2 | AMYLYX PHARMACEUTICALS INC | AMLX | 03237H101 | $60.5M | 10.95% | 4,349,885 | SH |
| 3 | ABIVAX SA | ABVX | 00370M103 | $60.4M | 10.94% | 542,696 | SH |
| 4 | VAXCYTE INC | PCVX | 92243G108 | $47.9M | 8.68% | 824,532 | SH |
| 5 | PHARVARIS N V | PHVS | N69605108 | $33.9M | 6.15% | 1,201,402 | SH |
| 6 | IMMIX BIOPHARMA INC | IMMX | 45258H106 | $33.6M | 6.09% | 3,693,585 | SH |
| 7 | CELCUITY INC | CELC | 15102K100 | $32.2M | 5.83% | 281,904 | SH |
| 8 | JAZZ PHARMACEUTICALS PLC | JAZZ | G50871105 | $30.8M | 5.58% | 162,961 | SH |
| 9 | DISC MEDICINE INC | IRON | 254604101 | $28.8M | 5.21% | 449,926 | SH |
| 10 | X4 PHARMACEUTICALS INC | XFOR | 98420X202 | $26.7M | 4.83% | 6,456,646 | SH |
| 11 | COGENT BIOSCIENCES INC | COGT | 19240Q201 | $24.1M | 4.37% | 626,635 | SH |
| 12 | MONOPAR THERAPEUTICS INC | MNPR | 61023L207 | $18.9M | 3.43% | 345,626 | SH |
| 13 | DYNE THERAPEUTICS INC | DYN | 26818M108 | $17.5M | 3.17% | 966,609 | SH |
| 14 | INVIVYD INC | IVVD | 00534A102 | $14.2M | 2.58% | 10,949,084 | SH |
| 15 | CANDEL THERAPEUTICS INC | CADL | 137404109 | $14.2M | 2.57% | 2,896,588 | SH |
| 16 | OCULIS HOLDING AG | OCS | H5870P102 | $13.7M | 2.49% | 516,761 | SH |
| 17 | OVID THERAPEUTICS INC | OVID | 690469101 | $9.2M | 1.68% | 4,166,666 | SH |
| 18 | INHIBIKASE THERAPEUTICS INC | IKT | 45719W205 | $6.5M | 1.18% | 3,863,445 | SH |
| 19 | ZURA BIO LTD | ZURA | G9TY5A101 | $4.4M | 0.80% | 739,960 | SH |
| 20 | ALTO NEUROSCIENCE INC | ANRO | 02157Q109 | $2.0M | 0.36% | 88,999 | SH |
| 21 | SATELLOS BIOSCIENCE INC | MSLE | 80401L803 | $2.0M | 0.36% | 350,000 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-03-31 | 2026-05-15 | $552.2M | 21 | 0001964437-26-000005 |
| 2025-12-31 | 2026-02-17 | $544.9M | 20 | 0001964437-26-000003 |
| 2025-09-30 | 2025-11-14 | $456.0M | 17 | 0001964437-25-000013 |